NO20084914L - Parenteral formulering inneholdende proton pumpeinhibitor sterilisert i dens siste beholder ved ioniserende straling - Google Patents

Parenteral formulering inneholdende proton pumpeinhibitor sterilisert i dens siste beholder ved ioniserende straling

Info

Publication number
NO20084914L
NO20084914L NO20084914A NO20084914A NO20084914L NO 20084914 L NO20084914 L NO 20084914L NO 20084914 A NO20084914 A NO 20084914A NO 20084914 A NO20084914 A NO 20084914A NO 20084914 L NO20084914 L NO 20084914L
Authority
NO
Norway
Prior art keywords
sterilized
formulation
proton pump
pump inhibitor
parenteral formulation
Prior art date
Application number
NO20084914A
Other languages
English (en)
Inventor
Mikael Bruells
Johanna Karlsson
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of NO20084914L publication Critical patent/NO20084914L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Disinfection or sterilisation of materials or objects, in general; Accessories therefor
    • A61L2/02—Disinfection or sterilisation of materials or objects, in general; Accessories therefor using physical processes
    • A61L2/08—Radiation
    • A61L2/081—Gamma radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2103/00—Materials or objects being the target of disinfection or sterilisation
    • A61L2103/05—Living organisms or biological materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Den foreliggende oppfinnelsen er relatert til en stabil sterilisert parenteral formulering omfattende en syre-mottakelig protonpumpeinhibitor. Formuleringen, en fast formulering omfattende den syre-mottakelige protonpumpeinhibitoren og eventuelt farmasøytisk akseptable tilsetninger, har blitt sterilisert i dens endelige beholder ved ioniserende stråling. Beholderen kan bestå av flere avdelinger og inneholde separat et egnet løsningsmiddel som er sterilisert, dvs. bestrålt, ved det samme tidspunktet som den faste formuleringen. Alternativt er det egnede løsningsmiddelet sterilisert separat eller aseptisk fremstilt. Den faste formuleringen er løst opp i et egnet løsningsmiddel før den blir administrert til pasienten, dvs. den blir preparert ex tempore. Den foreliggende oppfinnelsen er også relatert til den preparerte steriliserte parenterale formuleringen, den stabile faste formuleringen, fremgangsmåter for å oppnå nevnte parenterale formulering og nevnte faste formulering, så vel som til de terapeutiske anvendelser derav.
NO20084914A 2006-05-09 2008-11-21 Parenteral formulering inneholdende proton pumpeinhibitor sterilisert i dens siste beholder ved ioniserende straling NO20084914L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US79905806P 2006-05-09 2006-05-09
PCT/SE2007/000440 WO2007129961A1 (en) 2006-05-09 2007-05-07 Parenteral formulation comprising proton pump inhibitor sterilized in its final container by ionizing radiation

Publications (1)

Publication Number Publication Date
NO20084914L true NO20084914L (no) 2008-12-10

Family

ID=38667996

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20084914A NO20084914L (no) 2006-05-09 2008-11-21 Parenteral formulering inneholdende proton pumpeinhibitor sterilisert i dens siste beholder ved ioniserende straling

Country Status (13)

Country Link
US (1) US20090111856A1 (no)
EP (1) EP2018151A4 (no)
JP (1) JP2009536195A (no)
KR (1) KR20090024674A (no)
CN (1) CN101442985A (no)
AU (1) AU2007248949B2 (no)
BR (1) BRPI0711048A2 (no)
CA (1) CA2649946A1 (no)
MX (1) MX2008014283A (no)
NO (1) NO20084914L (no)
NZ (1) NZ572007A (no)
WO (1) WO2007129961A1 (no)
ZA (1) ZA200808824B (no)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2872336C (en) * 2012-05-09 2019-08-13 Icrom Spa Production of sterile active pharmaceutical ingredients
GB2513172A (en) * 2013-04-18 2014-10-22 Nupharm Lab Ltd Liquid dosage form and delivery system
CN103698430B (zh) * 2013-12-24 2015-01-21 江苏正大丰海制药有限公司 一种埃索美拉唑钠和注射用埃索美拉唑钠中杂质含量检测方法
CN105272965A (zh) * 2014-07-03 2016-01-27 上海汇伦生命科技有限公司 一种埃索美拉唑钠的纯化方法
GB201505347D0 (en) * 2015-03-27 2015-05-13 Salupont Consulting Ltd Sterilisation of s-nitrosothiols
US11793748B1 (en) * 2019-04-05 2023-10-24 Good Health, Llc Pharmaceutical compositions of aspirin for parenteral administration
US11666548B2 (en) * 2020-06-05 2023-06-06 Baxter International Inc. Parenteral nutrition formulation

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL75400A (en) * 1984-06-16 1988-10-31 Byk Gulden Lomberg Chem Fab Dialkoxypyridine methyl(sulfinyl or sulfonyl)benzimidazoles,processes for the preparation thereof and pharmaceutical compositions containing the same
US4678809A (en) * 1985-02-01 1987-07-07 Michael Phillips Injectable fomulations of disulfiram for the treatment of alcoholism
DE4438360C2 (de) * 1994-10-27 1999-05-20 Schott Glas Vorfüllbare partikelarme, sterile Einmalspritze für die Injektion von Präparaten und Verfahren zu ihrer Herstellung
IL133105A (en) * 1997-06-04 2004-09-27 Debio Rech Pharma Sa Implants for controlled release of pharmaceutically active principles and method for making same
SE9903831D0 (sv) * 1999-10-22 1999-10-22 Astra Ab Formulation of substituted benzimidazoles
PE20021017A1 (es) * 2001-04-03 2002-11-24 Pharmacia Corp Composicion parenteral reconstituible
WO2003077916A1 (en) * 2002-03-15 2003-09-25 Altana Pharma Ag Use of proton pump inhibitors for the treatment of noncardiac chest pain
KR100788778B1 (ko) * 2002-07-19 2007-12-27 윈스턴 파마슈티컬즈, 엘엘씨 벤즈이미다졸 유도체 및 이들의 프로톤 펌프 억제제의프로드럭으로서의 이용
CA2500908A1 (en) * 2002-10-04 2004-04-22 Elan Pharma International Limited Gamma irradiation of solid nanoparticulate active agents
JP2006505579A (ja) * 2002-10-25 2006-02-16 ファイザー・プロダクツ・インク 懸濁形態でのアリール複素環活性薬物の蓄積製剤
ATE466579T1 (de) * 2003-11-05 2010-05-15 Lyka Labs Ltd Verfahren zur herstellung von benzimidazolen
JP2005200409A (ja) * 2003-12-17 2005-07-28 Takeda Chem Ind Ltd 注射剤
TW200526268A (en) * 2003-12-17 2005-08-16 Takeda Pharmaceutical Injectable composition

Also Published As

Publication number Publication date
CN101442985A (zh) 2009-05-27
US20090111856A1 (en) 2009-04-30
AU2007248949A1 (en) 2007-11-15
CA2649946A1 (en) 2007-11-15
EP2018151A4 (en) 2012-07-18
AU2007248949B2 (en) 2010-04-08
KR20090024674A (ko) 2009-03-09
ZA200808824B (en) 2009-11-25
NZ572007A (en) 2010-12-24
BRPI0711048A2 (pt) 2011-08-23
MX2008014283A (es) 2008-11-18
WO2007129961A1 (en) 2007-11-15
EP2018151A1 (en) 2009-01-28
JP2009536195A (ja) 2009-10-08

Similar Documents

Publication Publication Date Title
MX2012006720A (es) Composicion farmceutica para el tratamiento de sindrome del ojo seco.
NO20090835L (no) Nye HIV-reverstranskriptaseinhibitorer
EA025302B8 (ru) Модуляторы кальциевого канала, активируемого высвобождением кальция, представляющие собой производные пиразола, и способы лечения немелкоклеточного рака легких
CL2008000946A1 (es) Compuestos derivados de pirrolopirimidina, inhibidores de cianasa jak3; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de rechazo de transplantes, enfermedades autoinmun
NO20084435L (no) C-MET proteinkinaseinhibitorer
EA201490489A1 (ru) Пуриновые производные и их применение в качестве модуляторов толл-подобного рецептора 7
NO20100301L (no) Forbedrete brimonidinsammensetninger for behandling av erytem
BRPI0806713A8 (pt) Composições de tiacumicinas estáveis
CL2008002129A1 (es) Compuestos derivados de (1h-indazol-3-il)-amidas sustituidas, inhibidores de quinasa; composicion farmaceutica; procedimiento de preparacion; y uso del compuesto para el tratamiento del cancer.
BR112017007239A2 (pt) inibidor da aurora a cinase, seus usos, e composição farmacêutica".
BR112014004560A2 (pt) compostos e composições como inibidores de c-kit quinase
UA118261C2 (uk) Хімічні сполуки
EA201270666A1 (ru) Соединения и фармацевтические композиции для снижения уровня мочевой кислоты
MX2009005881A (es) Derivados de 2-(piperidin-4-il)-4-fenoxi o fenilamino-pirimidina como inhibidores de la transcriptasa inversa no nucleosida.
MX386542B (es) Derivados de la 2,3-dihidro-isoindol-1-ona, como inhibidores de la btk quinasa y composiciones farmacéuticas que los incluyen.
EA202091999A3 (ru) Применение ингибиторов dpp iv
ECSP067076A (es) Derivados de pirimidina urea como inhibidores de la quinasa
CR11251A (es) Depsipeptidos ciclicos y usos de los mismos
AR058780A1 (es) Imidazopirazinas como inhibidores de quinasas dependientes de ciclina
WO2010102000A8 (en) High concentration no2 generating system and method for generating high concentration no2 using the generating system
CY1111197T1 (el) Tριαζολες χρησιμες ως αναστολεις πρετεϊνικων κινασων
ECSP088982A (es) Métodos para tratar enfermedades autoinmunes utilizando una molécula de fusión taci-ig
CL2015002608A1 (es) Compuesto de amino-pirazol y usos medicinales relacionados.
AR059294A1 (es) Derivados de indazol-heteroarilo
WO2009129531A3 (en) Bupivacaine formulation in a polyorthoester carrier

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application